Nevirapine was approved for use in 1996 in the US. Nevirapine belongs to the class of non-nucleotide reverse transcriptase inhibitors (NNRTIs). After the HIV virus enters the host cell, the HIV RNA strand is released, and the single strand RNA is reverse transcribed to form DNA by reverse transcriptase. The drug inhibits the formation of DNA, reduces the amount of HIV virus.